Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ipsen S.A. ADR (OP: IPSEY ) 30.68 -0.49 (-1.57%) Streaming Delayed Price Updated: 3:08 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Ipsen S.A. ADR < Previous 1 2 Next > Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal July 13, 2024 In other news, Sichuan Biokin Pharma has filed for an IPO on the Hong Kong Exchange; more on the Biosecure Act being pushed by US Speaker of the House Johnson. Via Talk Markets Topics Initial Public Offering Exposures Securities Market FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo June 11, 2024 The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... Via Benzinga Exposures Product Safety 3 Promising Biotech Stocks Flying Under the Radar November 08, 2023 Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks. Via InvestorPlace Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients August 21, 2023 Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs Via Benzinga Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class June 30, 2023 Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC: Via Benzinga Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases September 19, 2022 Via Benzinga Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients June 30, 2023 Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) Via Benzinga What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur May 22, 2023 On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... Via Benzinga Why These Two Biotech Stocks Blasted Higher This Week January 13, 2023 There's nothing like a big-premium buyout to send a company's share price to the moon. Via The Motley Fool 2 Tiny Nasdaq Stocks Making Major Merger Moves Monday January 09, 2023 The market is moving higher, and these small companies are helping. Via The Motley Fool France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline January 09, 2023 Via Benzinga Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting December 09, 2022 Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study Via Benzinga Why Merrimack Shares Are Surging Over 200% Today? November 09, 2022 Via Benzinga Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know November 01, 2022 October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... Via Benzinga AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know October 02, 2022 Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the... Via Benzinga Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure August 03, 2022 Via Benzinga This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday June 28, 2022 Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. Via Benzinga Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session June 27, 2022 Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. Via Benzinga The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies June 27, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why June 27, 2022 Ipsen SA (OTC: IPSEY) has Via Benzinga The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs May 03, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer May 03, 2022 Via Benzinga EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer March 25, 2022 Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have Via Benzinga Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy March 15, 2022 Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus... Via Benzinga A Peek Into The Markets: US Stock Futures Down Following Friday's Plunge January 24, 2022 Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones tumbled 450 points in the previous session. Investors are awaiting earnings results... Via Benzinga Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease January 24, 2022 Health Canada has approved Ipsen SA's (OTC: IPSEY) Sohonos (palovarotene capsules) in adults and children aged eight years & above for fibrodysplasia ossificans... Via Benzinga GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters December 17, 2021 Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY). Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday December 17, 2021 Good morning, investor! We're in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday! Via InvestorPlace Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful December 17, 2021 Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT)... Via Benzinga Ipsen Stock Declines After Pulling Rare Disease Application August 13, 2021 Ipsen (OTC: IPSEY) withdrew its US marketing application for palovarotene following discussions with the FDA indicating additional data analyses needed from two... Via Benzinga Exposures Product Safety < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
